GMP Regulatory Newsletter: Summary Scan | Week of 7/29/18

Laws, Regulations, Guidance, and Concept Papers

  • Another collection of FDA User Fee Rates for FY2019 was released (including those for drugs, outsourcing facilities, and biosimilars).
  • EMA published several items including a broad draft guideline that covers gene therapy products and the CAR-T family of products.
  • WHO published 3 guidance for consultation.
  • HPRA, Health Canada, and PIC/S each published 1 item.

To see the complete list of laws, regulations, guidance, and concept papers published this week, start your FREE GMP Regulatory Intelligence Trial today.

Enforcement:

  • Picked up this week with 5 warning letters:
    • 1 device
    • 1 compounding pharmacy
    • 3 pharma firms
  • We continue to provide the FDA requested information in our summaries (free consulting for anyone who has similar problems).
  • Several import alerts were put in place for failure to follow drug GMPs, including for one of Hospira’s sites in India with exceptions for ‘necessary’ medicines.

 

Learn more about how FDAzilla can help you achieve your quality and inspection preparation goals: get 483sInspector ProfilesEnforcement Analytics, and GMP Regulatory Intelligence. Contact us if you ever have questions at sales@fdazilla.com.

Sign up for your risk-free trial of the leading GMP intelligence newsletter.

Like this post? Don't forget to share it!

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Recent Posts

Govzilla Bug

Don’t miss out! Subscribe now

Experience the Power of Govzilla

Get your FREE account to search sites, inspections, & warning letters